HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NAD: Advertisers Must Substantiate Unpaid, Third-Party Claims Once They Link To Or Disseminate Them

Executive Summary

Texas-based hair care marketer Routine Wellness must substantiate an unpaid, third-party lifestyle blog’s review claiming the brand’s product is among the ‘5 best shampoos for women with thin hair’ because it linked to the review from its own social media pages, says the National Advertising Division in a review published 2 March.

You may also be interested in...

FTC Will Ask Congress To Sharpen Monetary Relief Authority Dulled By Supreme Court Ruling

Justice Breyer suggests FTC ask Congress to strengthen its enforcement rules. It is “free to ask Congress to grant it further remedial authority,” according to court opinion stating a rule the FTC has wielded for forty years to impose financial penalties doesn’t grant it authority to obtain equitable monetary relief.

Over The Counter 9 June 2023: Embracing AI/AR In Beauty, While Navigating Its Hurdles

In this episode of Over The Counter, HBW Insight speaks to Sampo Parkkinen, CEO and founder of Revieve, a firm that provides businesses with AI technology platforms to deliver a personalized brand experience. We discuss how artificial intelligence and augmented reality continue to shape beauty, where ChatGPT fits in and the importance of consumer privacy.

Doc On Call? Cosmetic Manufacturers May Need M.D. On Retainer Under MoCRA

Cosmetic manufacturers may need to retain a medical professional to determine if adverse events they receive are minor or serious given the looming deadline for maintaining records and reporting serious adverse events to the US FDA, says Locke Lord partner David Abramowitz.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts